Similarly, models with significant kidney or liver dysfunction are generally unsuitable, as impaired peptide clearance may heighten the risk of adverse effects
They are the architecture that makes the clinical outcomes possible
They likely reflect the difference between pathological IGF-1 excess (which does appear to increase cancer risk and accelerate ageing in some models) and normalisation of IGF-1 in individuals whose levels have declined below an optimal physiological range due to somatopause
Research suggests this coordinated signaling can produce more consistent GH pulses, enhance the precision of GH-related assays, and provide a broader view of metabolic, lipolytic, and regenerative mechanisms than either compound individually
Claims are checked against primary regulatory, trial, label, and public-health sources where available